Vaccinex, Inc. Common Stock
VCNX
VCNX was delisted on the 17th of December, 2024.
21 hedge funds and large institutions have $1.66M invested in Vaccinex, Inc. Common Stock in 2021 Q4 according to their latest regulatory filings, with 3 funds opening new positions, 4 increasing their positions, 4 reducing their positions, and 3 closing their positions.
36% more call options, than puts
Call options by funds: $136K | Put options by funds: $100K
0% more funds holding
Funds holding: 21 → 21 (0)
0% more first-time investments, than exits
New positions opened: 3 | Existing positions closed: 3
0% more repeat investments, than reductions
Existing positions increased: 4 | Existing positions reduced: 4
51% less capital invested
Capital invested by funds: $3.36M → $1.66M (-$1.7M)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Citadel Advisors
Miami,
Florida
|
+$140K |
| 2 |
Simplex Trading
Chicago,
Illinois
|
+$5.77K |
| 3 |
BlackRock
New York
|
+$2.16K |
| 4 |
Group One Trading
Chicago,
Illinois
|
+$2.16K |
| 5 |
TRCT
Tower Research Capital (TRC)
New York
|
+$1.44K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
OC
Oppenheimer & Co
New York
|
-$29.9K |
| 2 |
TC
Tacita Capital
Toronto,
Ontario, Canada
|
-$29K |
| 3 |
Susquehanna International Group
Bala Cynwyd,
Pennsylvania
|
-$14.1K |
| 4 |
UBS Group
Zurich,
Switzerland
|
-$9.38K |
| 5 |
Royal Bank of Canada
Toronto,
Ontario, Canada
|
-$2K |
VCNX Hedge Fund Activity: Q4 2021 in Review
21 of the 6,518 institutional investors tracked by Wall St. Rank reported a position in Vaccinex, Inc. Common Stock (VCNX) for Q4 2021, worth a combined $1.66M — down 51% from $3.36M a quarter earlier.
Fund positioning in VCNX was balanced in Q4 2021: 3 funds opened new positions, 3 closed out, 4 added to existing stakes and 4 trimmed.
The largest buyer was Citadel Advisors, opening a new position worth an estimated $140K. The largest seller was Oppenheimer & Co, cutting an estimated $29.9K.
- 21 institutional investors held Vaccinex, Inc. Common Stock (VCNX) as of Q4 2021, unchanged from Q3 2021.
- Funds reported $1.66M of Vaccinex, Inc. Common Stock stock for Q4 2021, down 51% quarter-over-quarter.
- 3 funds opened new Vaccinex, Inc. Common Stock positions in Q4 2021 and 3 closed out, a net change of 0 holders.
- The largest Vaccinex, Inc. Common Stock buyer in Q4 2021 was Citadel Advisors, an estimated $140K added.
- The largest Vaccinex, Inc. Common Stock seller in Q4 2021 was Oppenheimer & Co, an estimated $29.9K sold.
Based on aggregated 13F filings for Q4 2021.